These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8015799)

  • 1. Inhibition of tissue plasminogen activators and urokinase by human saliva.
    Haze C; Garfunkel AA; Eldor A; Kadouri A
    Oral Surg Oral Med Oral Pathol; 1994 Apr; 77(4):356-61. PubMed ID: 8015799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological characterization of plasminogen activators in human parotid saliva.
    Kjaeldgaard M; Kjaeldgaard A
    Arch Oral Biol; 1987; 32(12):855-7. PubMed ID: 3140770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue.
    Virtanen OJ; Sirén V; Multanen J; Färkkilä M; Leivo I; Vaheri A; Koskiniemi M
    Eur J Oral Sci; 2006 Feb; 114(1):22-6. PubMed ID: 16460337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification of epidermal plasminogen activator inhibitor.
    Hibino T; Izaki S; Izaki M
    FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The possible role of oral epithelial cells in tissue-type plasminogen activator-related fibrinolysis in human saliva.
    Sindet-Pedersen S; Gram J; Jespersen J
    J Dent Res; 1990 Jun; 69(6):1283-6. PubMed ID: 2113068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Lawrence D; Strandberg L; Grundström T; Ny T
    Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of proteases type plasminogen activator and their inhibitor in cornea.
    Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
    Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
    Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
    J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological characterization of plasminogen activators in human mixed saliva.
    Kjaeldgaard A; Kjaeldgaard M
    Acta Physiol Scand; 1986 Mar; 126(3):443-7. PubMed ID: 3515850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
    Wun TC; Reich E
    J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of a fast-acting specific inhibitor of plasminogen activator in human parotid saliva.
    Kjaeldgaard A; Kjaeldgaard M; Gaffney P
    Acta Physiol Scand; 1989 Nov; 137(3):379-83. PubMed ID: 2512768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased plasminogen activator inhibition levels in malignancy.
    de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
    Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of plasminogen activators and the growth of cultured human tumour cells.
    Scott GK
    Int J Biochem; 1988; 20(8):817-22. PubMed ID: 3139480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
    Kruithof EK; Tran-Thang C; Bachmann F
    Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
    Krishnamurti C; Alving BM
    Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.